Skip to main content


We're creating a new version of this page. See preview

  • Case Report
  • Open Access

Fibroepithelioma of pinkus in a 9-year-old boy: a case report

Cases Journal20081:21

  • Received: 30 May 2008
  • Accepted: 27 June 2008
  • Published:


Fibroepithelioma of Pinkus (FEP) is a rare indolent variety of basal cell carcinoma that is typically polypoid and located on the trunk of adult males aged 40–60 years. Basal cell carcinoma (including FEP) is very rare in the pediatric population. We are reporting such a case occurring in a 9-year-old boy.


  • Androgen Receptor
  • Basal Cell Carcinoma
  • Gene TP53
  • Hedgehog Pathway
  • Left Chest

Case presentation

A 9-year-old boy presented with a 6.0-mm polypoid erythematous nodule with ulceration on his left chest. An excisional biopsy was done. Histologically, the tumor revealed several foci of superficial basal cell carcinoma along the epidermis. In the dermis, the tumor was composed of basaloid epithelial anastomosing cords that were separated by fibrovascular stroma connected to the overlying epidermis (Figure 1). The histopathological features were that of a fibroepithelioma of Pinkus. The lesion was completely removed with clear biopsy margin. The patient is being followed for any possible local recurrence.

Figure 1


Fibroepithelioma of Pinkus (FEP) was first described as premalignant fibroepithelial tumor of the skin by Herman Pinkus in 1953 [1]. Although FEP is currently accepted as a variant of basal cell carcinoma (BCC), its classification still remains controversial. FEP may also be categorized as a variant of trichoblastoma, a benign counterpart of BCC [2].

Typically, the patients are male, 40–60 years of age and present with a single or multiple pedunculated or sessile nodules with broad base on the trunk or extremities [3]. The tumor may appear pink, red, brown or skin color with occasional ulceration. Histologically, the tumor is composed of long, thin, and branching strands of basal cell carcinoma anastomosing in fibrovascular stroma [3].

The primary differential diagnoses of FEP include BCC, trichoblastoma, and trichoepithelioma. The histologic appearance of the tumor is usually distinctive. Androgen receptor is expressed both in BCC and FEP but minimally in trichoblastomas [4]. On the other hand, Merkel cells are found in both FEP and trichoblastoma but they are absent in BCC [2].

The pathogenesis of FEP is still investigational. It is thought that a mutation in the tumor suppressor gene TP53 might predispose to the development of FEP [5]. Similarly to BCC, the suggestion has been made that mutations in the PATCHED gene, which provides inhibitory signal in the Hedgehog pathway, could also lead to the development of FEP [2, 3, 5]. Further studies are needed to further elucidate the genetic predisposition of FEP.

The definitive treatment for FEP is complete excision. The tumor is considered an indolent basal cell carcinoma with no metastatic potential. Other treatment options include electrodessication and curettage, cryosurgery, or Moh's micrographic surgery [2, 3].



Authors’ Affiliations

Department of Pathology, Creighton University Medical Center, Omaha, NE 68131, USA


  1. Pinkus H: Premalignant fibroepithelial tumors of skin. AMA Arch Derm Syphilol. 1953, 67: 598-615.View ArticlePubMedGoogle Scholar
  2. Su WM, Fromer E, Fung AM: Fibroepithelioma of Pinkus. Dermatology Online Journal. 2006, 12 (5): 2.PubMedGoogle Scholar
  3. Mehregan D: Premalignant Fibroepithelial Tumor (Pinkus Tumor). Emedicine. 2006, []Google Scholar
  4. Terrence MK, Ravis MS, Perkins MS, Moores BW, Billing DS: Expression of Androgen Receptor by Fibroepithelioma of Pinkus: Evidence Supporting Classification as a Basal Cell Carcinoma Variant?. Am J Dermatopathol. 2007, 29 (1): 7-12. 10.1097/ ArticleGoogle Scholar
  5. Saldanha G, Fletcher A, Slater DN: Basal cell carcinoma: a dermatopathological and molecular biological update. Br J Dermatol. 2003, 148 (2): 195-202. 10.1046/j.1365-2133.2003.05151.x.View ArticlePubMedGoogle Scholar


© Pan et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.